Zhejiang Medicine Co Ltd (600216) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin.
Total Assets Chart for Zhejiang Medicine Co Ltd
Zhejiang Medicine Co Ltd (600216) total assets for FY2025 were CNY 14.1B, a 2.1% change from FY2024. Zhejiang Medicine Co Ltd's total assets grew from CNY 946.4M in 1997 to CNY 14.1B in 2025 (1388.9% over 28 years). Total assets compound annual growth rate: 5-year CAGR of 6.1%, 10-year CAGR of 5.5%, 20-year CAGR of 9.7%.
Total Assets (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥12.13B
- Implied Share Price
- ¥12.61
- Enterprise Value
- ¥9.14B
- Revenue (TTM)
- ¥8.94B
- EBITDA
- ¥1.52B
- Profit Margin
- 9.01%
- Trailing P/E
- 15.01
- Forward P/E
- 13.39
- Price/Book (MRQ)
- 1.05
- Price/Sales (TTM)
- 1.36
- EV/EBITDA
- 5.71
- EV/Revenue
- 1.02
- Dividend Yield
- 2.20%
- Book Value
- ¥12.30
- Free Cash Flow (FY2025)
- ¥1.44B
- Free Cash Flow Yield
- 11.87%
Snapshot as of 23rd September 2026 — not point-in-time controlled, may lag the live market by a few days.